From The Editor

  1. The Growing Appetite For Obesity Drugs 4/3/2023

    New obesity drugs with unprecedented efficacy are coming into the market. Can they turn the tide in the global obesity epidemic?

  2. Commercialization Or Bust? 3/1/2023

    If you’re a biotech in the earlier stages of clinical development, is it now incumbent upon leadership to build out the capabilities necessary for regulatory submission and commercialization, in case the right deal doesn’t materialize?

  3. Choosing Your Battles 2/1/2023

    Should business leaders speak out on the social and political issues that intermingle with the buying and selling of goods and services? Opinions vary … widely.

  4. The Next Big Thing 1/3/2023

    Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?

  5. Only The Creative Survive 12/1/2022

    Looking through my 2022 coverage areas, and in reading through my colleagues’ outlook articles, what was most compelling to me were not necessarily the specific issues raised, but how leadership approached those issues to create solutions.

  6. Channeling, Or Cancelling, Jack Welch 11/1/2022

    Although some of Jack Welch’s past leadership practices have come under fire in recent years, it’s safe to say that one of the most successful CEOs in recent history might have some useful ideas and strategy worth remembering.

  7. Tiptoeing Toward A Cure For Type 1 Diabetes 10/3/2022

    In working on this month’s cover story, which features Imagine Pharma, a preclinical stage biotech based in Pittsburgh, it was hard not to get swept up in the enthusiasm and promise of the company’s autologous cell therapy treatment for Type 1 diabetes (T1D).

  8. A D&I Program Worth Replicating 9/1/2022

    Ninety-four percent of PhRMA’s member companies responding to a survey published in December 2020 reported the existence of “employee resource groups” within their organizations, defined as an “employer recognized group of employees who share the concerns of a common race, gender, national origin, or sexual orientation.”

  9. Representation Matters. Location Does Too. 8/1/2022

    Representation at the top of any profession, whether jurisprudence or biotechnology, works as an accelerator for younger generations to follow.

  10. Scouting Turbulence For Opportunity 7/1/2022

    With bad news in the headlines at home and globally, and a seesawing public market capable of wiping years of value from company books almost overnight, it can be difficult to remain focused on the bread-and-butter tasks that keep a company afloat.